Nie, W.(2019). Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade. Annals of Oncology, 30, ii62. doi:10.1093/annonc/mdz063.068

Nie, W. "Advanced Non-small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Anti-programmed Cell Death (PD)-1 and Anti-programmed Deathligand 1 (PD-L1) Blockade". Annals of Oncology, 30 ( 2019 ): ii62.